---
title: "Atorvastatin Adverse Event Confirmation in Older Medicare Beneficiaries Using Sequential Target-Tr"
id: "medrxiv-11-beyond-signal-detection-sequential-target-trial-emulations-to-confirm"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-11-beyond-signal-detection-sequential-target-trial-emulations-to-confirm"
content_type: "clinical_feed_article"
specialty: "Pharmacology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1?rss=1"
published_at: "2026-08-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Atorvastatin Adverse Event Confirmation in Older Medicare Beneficiaries Using Sequential Target-Tr
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-11-beyond-signal-detection-sequential-target-trial-emulations-to-confirm
- **Specialty:** [Pharmacology](https://medichelpline.com/clinical-feed/pharmacology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1?rss=1)
- **Published At:** 2026-08-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study used sequential **target-trial emulation** to confirm previously detected adverse drug event (ADE) signals for **atorvastatin** initiation in older, statin‑naïve Medicare beneficiaries discharged after myocardial or cerebral infarction. - Data source: Medicare fee‑for‑service claims from 2017–2019; 70,130 eligible patients, of whom 39,948 initiated atorvastatin and 19,182 initiated another new outpatient medication. - Design: Up to 14 nested daily trials (Trials 0–13) anchored at discharge to eliminate immortal time; primary analyses stacked all eligible trials; sensitivity analysis restricted to Trials 0–1 for improved covariate balance. - Treatment comparisons: initiation of **atorvastatin** (A1) versus initiation of any other new outpatient medication (A2); A0 (no new medication) retained for eligibility only. - Analytic approach: per‑protocol effects estimated with inverse‑probability‑of‑treatment and inverse‑probability‑of‑censoring weighting; artificial censoring for treatment deviation; death treated as competing risk using Fine–Gray models. - Outcome definitions: refined, more homogeneous outcomes within families (hemorrhagic events, cardiac valve disorders, musculoskeletal injuries, sensory symptoms, abnormal labs, hyperglycemic events) using Clinical Classifications Software Refined and validated algorithms; incident events required no baseline codes. - Confirmation criteria: (1) within‑outcome Benjamini–Hochberg q ≤ 0.05 with subdistribution hazard ratio (sHR) > 1.0; and (2) both median and 2.5th percentile of bias‑adjusted sHR > 1.0 across 5,000 Monte Carlo draws of probabilistic quantitative bias analysis (confounder–outcome RR 1.25–3.00; prevalence difference 0.05–0.25). - Absolute risk measures and numbers needed to harm (NNH) reported; stratified analyses by time windows (1–30, 31–91, 92–182 days), age, sex, and race were conducted. - Confirmed associations included acute hemorrhagic cerebrovascular disease overall (sHR 1.43; 95% CI 1.00–2.04; risk difference 0.5%; NNH 205), stronger in first 30 days (sHR 2.20), related intracranial hemorrhage signals, late nonrheumatic/unspecified valve disorders (days 92–182; sHR 1.48–1.58), cardiac valve intervention (sHR 1.74–1.83), musculoskeletal injuries among men (sHR 1.66–1.94), general sensation/perception symptoms and dizziness among non‑White patients (sHR 1.40–1.43) in the unrestricted trial set, acute hepatic failure overall (sHR 1.61–1.72), and biliary tract disease among women (sHR 1.45–1.49). - Several prior signals, including prediabetes and acute posthemorrhagic anemia, did not meet the dual confirmation criteria. - For each confirmed association, the proportion of bias‑adjusted Monte Carlo draws remaining above the null was 1.00. - Authors conclude that sequential emulations with refined definitions, multiplicity control, trial restriction, and probabilistic bias analysis provide rigorous confirmation of several ADE signals for atorvastatin in older adults, with modest but clinically relevant absolute excess risks; external validation in independent data is recommended.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=PyMdF7cvxgVFCx9HVpJfFbjRRFZ8gZPeVMyYjQVyJOw-1786715119.490152-1.2.1.1-EVQu2YcYZs96Sa4FxUuBDMIRUTtjaMp9fNR95i4UBT_GGvIFYO7ZjYfWVGDoBmJV) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Beyond Signal Detection: Sequential Target Trial Emulations to Confirm Previously Detected Adverse Drug Event Signals for Atorvastatin in Older Medicare Beneficiaries [ View ORCID Profile](http://orcid.org/0000-0002-4318-2970)Christopher G. Rowan doi: https://doi.org/10.64898/2026.08.12.26360302 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Christopher G. Rowan Veritas Research Foundation * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Christopher%2BG.%2BRowan%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Rowan%20CG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AChristopher%2BG.%2BRowan%2B) * [ORCID record for Christopher G. Rowan](http://orcid.org/0000-0002-4318-2970 "Open in new tab") * For correspondence: crowan@veritasrf.org * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1278370/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1278370/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1278370/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1278370/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1278370/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract **Importance:** Active pharmacovigilance via sequential target trial emulation can detect adverse drug event (ADE) signals missed by spontaneous reporting, yet signals identified through high-dimensional screening require rigorous, pre-specified confirmation that addresses residual confounding, outcome heterogeneity, multiplicity, and absolute risk. **Objective:** To confirm or refute previously detected ADE signals associated with atorvastatin initiation among older adults by applying refined and more homogeneous outcome definitions, expanded family- and component-level exclusions, within-outcome false-discovery-rate control, and probabilistic quantitative bias analysis within a sequential target-trial framework. **Design, Setting, and Participants:** Confirmatory sequential target trial emulation study using Medicare fee-for-service claims (2017–2019). Eligible participants were statin-naïve beneficiaries aged ≥65 years hospitalized for myocardial infarction or cerebral infarction (primary diagnosis, length of stay ≥3 days) and discharged home. Up to 14 nested daily trials (Trials 0–13) were constructed beginning on the discharge date, with eligibility, treatment assignment, and follow-up synchronized at each trial origin to eliminate immortal time. Primary analyses stacked all eligible trials; a pre-specified sensitivity analysis restricted inference to Trials 0 and 1, which achieved superior covariate balance (maximum standardized mean difference 1.0 and (2) both the median and 2.5th percentile of the bias-adjusted sHR remaining >1.0 across 5,000 Monte Carlo draws of probabilistic quantitative bias analysis (confounder–outcome risk ratio 1.25–3.00; prevalence difference 0.05–0.25). Absolute risks, risk differences, and numbers needed to harm (NNH) were reported. Stratified analyses examined time windows (1–30, 31–91, 92–182 days), age, sex, and race. **Results:** Of 70,130 eligible patients, 39,948 initiated atorvastatin and 19,182 initiated another new medication. After weighting, baseline covariates were closely balanced. Acute hemorrhagic cerebrovascular disease was confirmed overall (sHR 1.43, 95% CI 1.00–2.04; risk difference 0.5%; NNH 205) and more strongly in the first 30 days (sHR 2.20, 1.35–3.58); the association persisted in Trials 0 and 1 (sHR 1.50, 1.02–2.20). Related early intracranial hemorrhage signals were likewise confirmed. Nonrheumatic and unspecified valve disorders were confirmed in days 92–182 (sHR 1.48–1.58), as was cardiac valve intervention overall (sHR 1.74–1.83). Sprains, strains, and related composites were confirmed among men (sHR 1.66–1.94). General sensation/perception symptoms and dizziness were confirmed among non-White patients (sHR 1.40–1.43) but only in the unrestricted trial set. Acute hepatic failure was confirmed overall (sHR 1.61–1.72), and biliary tract disease among women (sHR 1.45–1.49). For every confirmed association the proportion of bias-adjusted draws remaining above the null was 1.00. Multiple prior signals, including prediabetes and acute posthemorrhagic anemia, failed the dual confirmation criteria. **Conclusions:** Sequential target-trial emulations with refined outcome definitions, within-outcome multiplicity control, restriction to optimally balanced early trials, and probabilistic quantitative bias analysis confirmed several ADE signals associated with atorvastatin initiation in older adults—most notably early hemorrhagic cerebrovascular events, cardiac valve disorders and interventions, musculoskeletal injuries in men, and selected hepatobiliary events—while attenuating others. Absolute excess risks were modest yet clinically relevant in a high-risk post-infarction population. These findings support a two-stage active pharmacovigilance paradigm (signal detection followed by rigorous confirmation) and justify heightened clinical vigilance for the confirmed events, while underscoring the need for external validation in independent populations and data sources. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Protocols ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethics committee/IRB of Rutgers University gave ethical approval for this research (eIRB protocol #Pro2024000224) I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability This study was completed in part by data resources provided by the Institute for Health Data Core at Rutgers University, available at: http://www.ifhcore.rutgers.edu. The data supporting the research initiative, titled Pharmacovigilance 2.0: Elderly, Disabled, and Disadvantage Populations and conducted under the principal investigator Christopher Rowan, were obtained from the Centers for Medicare & Medicaid Services (CMS) under Data Use Agreement number RSCH-2024-70249. These data contain protected health information subject to the Privacy Act and HIPAA regulations. Due to privacy, confidentiality, and contractual restrictions imposed by CMS, the datasets are not publicly available and cannot be shared by the authors. Qualified researchers interested in accessing similar data may apply independently through the Research Data Assistance Center (ResDAC) at https://resdac.org/ and execute their own Data Use Agreement with CMS. ## Funder Information Declared Veritas Research Foundation Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.12.26360291v1 "Additive Multilocus Burden and Epistatic Interactions Improves Genetic Risk Predictions for Complex Diseases") Posted August 14, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/14/2026.08.12.26360302.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.12.26360302v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/14/2026.08.12.26360302.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Beyond Signal Detection: Sequential Target Trial Emulations to Confirm Previously Detected Adverse Drug Event Signals for Atorvastatin in Older Medicare Beneficiaries Christopher G. Rowan medRxiv 2026.08.12.26360302; doi: https://doi.org/10.64898/2026.08.12.26360302 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360302v1%26text%3DBeyond%2520Signal%2520Detection%253A%2520Sequential%2520Target%2520Trial%2520Emulations%2520to%2520Confirm%2520Previously%2520Detected%2520Adverse%2520Drug%2520Event%2520Signals%2520for%2520Atorvastatin%2520in%2520Older%2520Medicare%2520Beneficiaries "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360302v1%26t%3DBeyond%2520Signal%2520Detection%253A%2520Sequential%2520Target%2520Trial%2520Emulations%2520to%2520Confirm%2520Previously%2520Detected%2520Adverse%2520Drug%2520Event%2520Signals%2520for%2520Atorvastatin%2520in%2520Older%2520Medicare%2520Beneficiaries "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360302v1%26title%3DBeyond%2520Signal%2520Detection%253A%2520Sequential%2520Target%2520Trial%2520Emulations%2520to%2520Confirm%2520Previously%2520Detected%2520Adverse%2520Drug%2520Event%2520Signals%2520for%2520Atorvastatin%2520in%2520Older%2520Medicare%2520Beneficiaries%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.12.26360302v1%26title%3DBeyond%2520Signal%2520Detection%253A%2520Sequential%2520Target%2520Trial%2520Emulations%2520to%2520Confirm%2520Previously%2520Detected%2520Adverse%2520Drug%2520Event%2520Signals%2520for%2520Atorvastatin%2520in%2520Older%2520Medicare%2520Beneficiaries "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.12.26360302) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.12.26360302v1&count=horizontal&via=&text=Beyond%20Signal%20Detection%3A%20Sequential%20Target%20Trial%20Emulations%20to%20Confirm%20Previously%20Detected%20Adverse%20Drug%20Event%20Signals%20for%20Atorvastatin%20in%20Older%20Medicare%20Beneficiaries&counturl=www.medrxiv.org/content/10.64898/2026.08.12.26360302v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (604) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (323) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4715) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (469) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (403) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (633) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1601) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15717) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1187) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6921) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (723) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1043) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4908) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1416) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1715) * [Hematology](https://www.medrxiv.org/collection/hematology) (571) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1318) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16189) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1151) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (655) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (713) * [Neurology](https://www.medrxiv.org/collection/neurology) (7091) * [Nursing](https://www.medrxiv.org/collection/nursing) (358) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1064) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1214) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (990) * [Oncology](https://www.medrxiv.org/collection/oncology) (3536) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1023) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (384) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (437) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (460) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (136) * [Pathology](https://www.medrxiv.org/collection/pathology) (700) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1760) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (726) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (754) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5771) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9600) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2351) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-ph
## Related Clinical Research

- [Atorvastatin-loaded frankincense SNEDDS thermoresponsive hydrogel improves wound healing in a rat](https://medichelpline.com/clinical-feed/pubmed-42542257.md) (DOI: 10.1016/j.ijpharm.2026.127264)
- [Mechanisms of Statin–Ezetimibe Combinations Revealed by Boolean Modeling and Transcriptomics](https://medichelpline.com/clinical-feed/pubmed-42678094.md) (DOI: 10.1002/psp4.70329)
- [Pharmacogenomic landscape in Thailand: Array-based PGx profiling and EMR-linked medication exposure](https://medichelpline.com/clinical-feed/plos-one-9-pharmacogenomic-landscape-in-thailand-array-based-profiling-and-emr-linked.md)
- [Widening medication adherence gap: impact on modern therapeutics and system solutions](https://medichelpline.com/clinical-feed/plos-medicine-0-the-widening-medication-adherence-gap.md)
- [Undiagnosed type 2 diabetes presenting as DKA with hypertriglyceridemia-induced acute pancreatitis](https://medichelpline.com/clinical-feed/cmaj-1-undiagnosed-type-2-diabetes-presenting-as-diabetic-ketoacidosis-with.md)

## Navigation
- [← Back to Pharmacology Feed](https://medichelpline.com/clinical-feed/pharmacology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.